Samsung Biologics posts Q3 profit drop despite higher revenue
Samsung Biologics reported a 21.2% decline in third-quarter net profit to 391.1 billion won, while revenue rose 18.5% to 1.49 trillion won.
The biotech subsidiary of Samsung Group announced third-quarter earnings of 391.1 billion won, down 21.2% from a year earlier. Operating profit edged up slightly to 640.1 billion won, surpassing the prior year's 633.5 billion won. Revenue increased by 18.5% to reach 1.49 trillion won. The company, a contract development and manufacturing organization, said the operating profit exceeded the average market estimate by 5.1%. No net-profit forecast was provided.
Why it matters
The results show how a major CDMO can grow sales while still facing profit pressure, affecting investors and biotech clients.
In this story
